| human | Q5 |
| P10638 | Iris-AperTO author ID | 03779 |
| P496 | ORCID iD | 0000-0002-7132-6484 |
| P1153 | Scopus author ID | 55256240200 |
| P27 | country of citizenship | Italy | Q38 |
| P69 | educated at | University of Turin | Q499911 |
| P108 | employer | Harvard Medical School | Q49121 |
| Massachusetts General Hospital | Q126412 | ||
| University of Turin | Q499911 | ||
| P735 | given name | Giulia | Q127733 |
| Giulia | Q127733 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| P937 | work location | Turin | Q495 |
| Q60889738 | Abstract LB-75: Blood-based molecular detection of acquired resistance to anti-EGFR therapies in colorectal cancer patients |
| Q39120801 | Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. |
| Q38821392 | Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. |
| Q24563539 | Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer |
| Q51752412 | Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. |
| Q38699032 | Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients |
| Q99591091 | Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment |
| Q42183079 | Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. |
| Q29615778 | Detection of circulating tumor DNA in early- and late-stage human malignancies |
| Q40291585 | Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. |
| Q27853380 | Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial |
| Q24604601 | Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer |
| Q38706872 | Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer |
| Q38916276 | Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. |
| Q57280718 | Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients |
| Q42689844 | Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor. |
| Q38249332 | Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance |
| Q38377594 | Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. |
| Q49551908 | Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. |
| Q39157824 | Integrating liquid biopsies into the management of cancer |
| Q57280710 | Liquid biopsies to evaluate early therapeutic response in colorectal cancer: Figure 1 |
| Q27853393 | MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. |
| Q40026210 | MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. |
| Q40179385 | Minimal residual disease in breast cancer: in blood veritas |
| Q43142381 | Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer |
| Q38764035 | Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer |
| Q38376337 | Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers |
| Q47382737 | Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer |
| Q38776411 | Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma |
| Q27853340 | The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer |
| Q48562940 | Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. |
| Q38275060 | Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer |
| Q36989342 | Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition |
| Q90156140 | Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients |
Search more.